Crohn's Disease...Elan Press Release: TYSABRI® Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week Article
TYSABRI Data Support Maintenance Efficacy In Patients Who Had Previously Failed Infliximab Therapy

DUBLIN, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 24, 2006--Elan Corporation, plc (NYSE:ELN) and Biogen Idec (NASDAQ:BIIB) announced today data that show TYSABRI® (natalizumab) maintained remission in Crohn's disease patients (CD) treated for longer than 2 years. These data, presented this week at the 14th United European Gastroenterology Week (UEGW) in Berlin, Germany, and at the Annual American College of Gastroenterology (ACG) in Las Vegas, Nevada, were part of an open label extension study of patients who participated in the ENACT-2 trial.

Ninety-three percent (93%) of TYSABRI patients who were in remission at month 12 of ENACT-2, were still in remission following 6 additional TYSABRI infusions in the open-label extension study (OLE) and 86% were still in remission after 12 additional infusions.

"What is truly exciting is that patients who enter remission on TYSABRI may remain in remission in the long-term without loss of efficacy over time. These data are a significant advance for the field and suggest that TYSABRI may be an alternative biologic outside the anti-TNF class for patients suffering from Crohn's disease," said Remo Panaccione MD, Director, Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada, who presented the data at UEGW.Click Here for Complete Elan Press Release